NEW YORK, Oct. 31 /PRNewswire-FirstCall/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation (Amex: CVM). The full 56-page report can be found at http://www.crystalra.com.
CEL-SCI Corporation develops immune-based cancer and infectious disease therapies. Its primary product candidate is Multikine(R), a next-generation, comprehensive immunotherapy that targets treatment-naive, newly diagnosed head and neck cancer. Multikine(R) is a mixture of biologically active natural cytokines designed to closely mimic the natural immune system.
Differing from other immunotherapies, Multikine(R) has the following attributes: (1) multitargeted-it activates multiple cellular components of the immune system to fight cancer; (2) administered as a first-line therapy before the patient receives surgery, chemotherapy, or radiotherapy, which is when the immune system is strongest; (3) kills roughly 50% of tumor cells before the standard of care is begun; (4) renders the residual live cancer cells that survive treatment more susceptible to the effects of radiation and chemotherapy, thereby potentially enhancing these treatments; and (5) is shown to be safe and well tolerated in Phase I and II clinical trials. In over 200 patients treated in CEL-SCI's trials, no severe side effects associated with Multikine(R) were reported.
Multikine(R) is now ready for a Phase III clinical trial for advanced primary head and neck cancer. In Phase III, CEL-SCI intends to administer Multikine(R) prior to the currently accepted and routinely used first-line standard of care treatment-surgery followed by radiation/chemotherapy. The Company hopes to show that Multikine(R) plus the standard of care increases patients' overall survival. CEL-SCI believes that a positive Phase III outcome could enable Multikine(R) to be routinely included as part of the standard of care for all advanced primary head and neck cancer patients. Multikine(R) may also have applications in melanoma and breast, skin, bladder, and cervical cancer.
Also in CEL-SCI's pipeline are two other platforms, a Ligand Epitope Antigen Presentation System (L.E.A.P.S.)(TM) and Antigen-Directed Apoptosis (AdapT), with a second product candidate, CEL-1000. CEL-1000, derived from L.E.A.P.S.(TM), is poised for trials as a potential adjuvant to boost vaccine immunogenicity for viral encephalitis, herpes simplex, malaria, hepatitis B, and the avian flu.
About Crystal Research Associates, LLC
Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small and mid-cap companies. Crystal Research Associates' unique and novel product, the Executive Informational Overview(R) (EIO(R)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(R) presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(R) details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, audited financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City, Delray Beach, Montreal, and Toronto. Crystal Research Associates has been compensated by the Company in cash of thirty-five thousand U.S. dollars and two hundred thousand options/warrants to purchase CEL-SCI stock for its services in creating the base report, for updates, and for printing.
Forward-Looking Safe Harbor Statement
Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements including: limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including Forms 10-K, 10-Q, 8-K, and other forms filed with the Securities and Exchange Commission ("SEC").
These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.
|SOURCE Crystal Research Associates, LLC|
Copyright©2007 PR Newswire.
All rights reserved